Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of COPD with a moderate to severe classification~* Current and former smokers with a history of at least 10 pack-years of cigarette smoking.~-Post-bronchodilator FEV1 must be ≥30% and \<80% predicted normal value-~Exclusion Criteria:~* Pregnancy~* Primary asthma diagnosis; Poorly controlled COPD defined as acute worsening of COPD that required treatment with corticosteroids or antibiotics in the 6-week interval prior to Screening or between Screening and Visit 2;~* Clinically significant abnormal ECG~* Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, and uncontrolled sleep apnea; Cancer that was not in complete remission for at least 5 years;~* Diagnosis of angle closure glaucoma~* A documented myocardial infarction within 1 year of Screening.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GP MDI 28.8 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 28.8 micrograms
- GP MDI 14.4 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 14.4 micrograms
- GP MDI 7.2 micrograms (Type: ACTIVE_COMPARATOR): Glycopyrronium Metered Dose Inhaler 7.2 micrograms
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo Inhalation Aerosol

Based on this trial design, predict the completion outcome and termination type (if applicable).